Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 3/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.42 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | KLK3 | P07288 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4041087 | 0.84 | GAA (0.34) | PDCD1CD274TACR3KDM4EPOLB | |
| SCHEMBL4038841 | 0.84 | DRD2 (0.42) | PDCD1CD274TACR3KLK3KDM4E | |
| SCHEMBL4043225 | 0.84 | CD274 (0.34) | PDCD1CD274KDM4ETDP1L3MBTL1 | |
| SCHEMBL4042421 | 0.84 | CD274 (0.40) | PDCD1CD274KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL4042657 | 0.83 | NPC1 (0.41) | TACR3SMN1; SMN2LMNAKMT2ATSHR | |
| SCHEMBL4042014 | 0.82 | GRIA1 (0.34) | KDM4ETDP1L3MBTL1DRD4 | |
| SCHEMBL4043112 | 0.81 | CD274 (0.58) | PDCD1CD274KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL4041484 | 0.80 | EGLN1 (0.37) | PDCD1CD274TACR3KDM4ESMN1; SMN2 | |
| SCHEMBL4039070 | 0.80 | CYP11B2 (0.39) | KDM4EHTTL3MBTL1DRD2DRD3 | |
| SCHEMBL4045032 | 0.79 | SMN1; SMN2 (0.36) | CD274KDM4ESMN1; SMN2POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1319659-B1 | TRIAZINONES AND MEDICINAL USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-03-11 | — | — | EP | claimed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | claimed |
| EP-1380342-B1 | COMPLEX CATALYST, PROCESS FOR PRODUCING THE COMPLEX CATALYST, AND PROCESS FOR PRODUCING ALCOHOL DERIVATIVE WITH THE COMPLEX CATALYST | SUMITOMO CHEMICAL CO (JP) | 2009-07-01 | — | — | EP | disclosed |
| EP-1319659-B1 | TRIAZINONES AND MEDICINAL USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-6995110-B2 | Complex catalyst, process for producing the complex catalyst, and process for producing alcohol derivative with the complex catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20040077487-A1 | Complex catalyst, process for producing the complex catalyst, and process for producing alchohol derivative with the complex catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1380342-A1 | COMPLEX CATALYST, PROCESS FOR PRODUCING THE COMPLEX CATALYST, AND PROCESS FOR PRODUCING ALCOHOL DERIVATIVE WITH THE COMPLEX CATALYST | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | GRIK1, GRIK3, GRIK2 | PDCD1 3074/4885CD274 2129/4885TACR3 283/4885 |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | GRIK3, GRIK1, GRIK2 | PDCD1 3741/4885CD274 3053/4885TACR3 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.